Halda has invented RIPTAC therapeutics, a novel drug modality that selectively targets cancer cells by bringing two proteins together, causing the loss of an essential function for cell survival and leading to cancer cell death. This technology overcomes the limitations of drug resistance commonly seen in current precision cancer medicines. Halda has a pipeline of RIPTAC therapeutics for major cancer types and aims to address the unmet needs of drug-resistant cancer patients. With its headquarters and state-of-the-art labs in Science Park, New Haven, CT, Halda is a research-stage drug discovery company that seeks to create the next generation of precision medicine based on its proprietary platform technology.